A share price of Nektar Therapeutics [NKTR] is currently trading at $0.86, up 1.67%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NKTR shares have gain 9.97% over the last week, with a monthly amount glided 6.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on January 08, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $4. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 10, 2024, and set its price target to $6.50. On November 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $7 on the stock. Rodman & Renshaw initiated its recommendation with a Buy and recommended $2 as its price target on June 28, 2024. In a note dated November 09, 2023, TD Cowen upgraded an Outperform rating on this stock.
Nektar Therapeutics experienced fluctuations in its stock price throughout the past year between $0.65 and $1.93. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $0.86 at the most recent close of the market. An investor can expect a potential return of 1847.67% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Trailing Twelve Months sales for Nektar Therapeutics [NASDAQ:NKTR] were 93.14M which represents -0.08% decline. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.46%, Pretax Profit Margin comes in at -1.81%, and Net Profit Margin reading is -1.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -1.74 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8352 points at the first support level, and at 0.8126 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8796, and for the 2nd resistance point, it is at 0.9014.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nektar Therapeutics [NASDAQ:NKTR] is 4.24. Also, the Quick Ratio is 4.24, while the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 1.70, the price to book ratio is 3.24.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Feb 19 ’25 when 10300.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Feb 19 ’25 to sell 11040.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 23774.0 shares on Feb 19 ’25.
